ALVO Stock Recent News

The FDA concludes the reinspection of Alvotech's (ALVO) facility in Iceland. The company believes that it may receive approval for biosimilar candidates, AVT02 and AVT04, in the United States.

From a technical perspective, Alvotech (ALVO) is looking like an interesting pick, as it just reached a key level of support. ALVO's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.

Alvotech (NASDAQ:ALVO ) Q3 2023 Earnings Conference Call November 29, 2023 8:00 AM ET Company Participants Benedikt Stefansson - Senior Director of IR and Global Communications Robert Wessman - Chairman and CEO Anil Okay - Chief Commercial Officer Joel Morales - CFO Conference Call Participants Mikaela Franceschina - Barclays Niall Alexander - Deutsche Bank Thibault Boutherin - Morgan Stanley Operator Welcome to Alvotech's Earnings Call for the First Nine Months of 2023. At this time, all participants are in a listen-only mode.

REYKJAVIK, Iceland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies London Healthcare Conference taking place in London on November 14-16, 2023.

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announces its participation in the Morgan Stanley 21st Annual Global Healthcare Conference in New York on September 11–13, 2023.

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first six months of 2023, after U.S. markets close on Wednesday, August 30, 2023.

Alvotech specializes in biosimilar medicines. The company received a complete response letter from the FDA regarding the manufacturing facility for its Humira biosimilar, AVT02.

Alvotech has a resolvable CRL. This took down the stock, but when resolved, that could create a quick spike. Ordinarily, this would be an opportunity, except for Alvotech's poor cash position.

REYKJAVIK, Iceland, May 03, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2023, after U.S. markets close on Thursday, May 18, 2023.

Alvotech's shares decline as it receives a complete response letter for biosimilar candidate, AVT02, treating autoimmune disorders.